Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

Open access
Simões, Eric A F, Forleo-Neto, Eduardo, Geba, Gregory P, Kamal, Mohamed, Yang, Feng, Cicirello, Helen, Houghton, Matthew R, Rideman, Ronald, Zhao, Qiong, Benvin, Sarah L, Hawes, Alicia, Fuller, Erin D, Wloga, Elzbieta, Pizarro, Jose M Novoa, Munoz, Flor M, Rush, Scott A, McLellan, Jason S, Lipsich, Leah, Stahl, Neil, Yancopoulos, George D, Weinreich, David M, Kyratsous, Christos A, Sivapalasingam, Sumathi · 2021 · Clinical Infectious Diseases

Abstract

Background: Respiratory syncytial virus (RSV) is a major cause of childhood medically attended respiratory infection (MARI). Methods: We conducted a randomized, double-blind, placebo-controlled phase 3 trial in 1154 preterm infants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can bind and block a conserved epitope on RSV A and B subtypes, for the prevention of RSV MARI. The primary endpoint was proportion of subjects with RSV-confirmed hospitalizations or outpatient lower respiratory tract infection (LRTI). Results: There were no significant differences between primary endpoint rates (8.1%, placebo; 7.7%, 1-dose; 9.3%, 2-dose). Suptavumab prevented RSV A infections (relative risks, .38; 95% confidence interval [CI], .14–1.05 in the 1-dose group and .39 [95% CI, .14–1.07] in the 2-dose group; nominal significance of combined suptavumab group vs placebo; P = .0499), while increasing the rate of RSV B infections (relative risk 1.36 [95% CI, .73–2.56] in the 1-dose group and 1.69 [95% CI, .92–3.08] in the 2-dose group; nominal significance of combined suptavumab group vs placebo; P = .12). Sequenced RSV isolates demonstrated no suptavumab epitope changes in RSV A isolates, while all RSV B isolates had 2–amino acid substitution in the suptavumab epitope that led to loss of neutralization activity. Treatment emergent adverse events were balanced across treatment groups. Conclusions: Suptavumab did not reduce overall RSV hospitalizations or outpatient LRTI because of a newly circulating mutant strain of RSV B. Genetic variation in circulating RSV strains will continue to challenge prevention efforts. Clinical Trials Registration: NCT02325791.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa951

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 167

Metadata

Authors
Simões, E. A. F., Forleo-Neto, E., Geba, G. P., Kamal, M., Yang, F., Cicirello, H., Houghton, M. R., Rideman, R., Zhao, Q., Benvin, S. L., Hawes, A., Fuller, E. D., Wloga, E., Pizarro, J. M. N., Munoz, F. M., Rush, S. A., McLellan, J. S., Lipsich, L., Stahl, N., Yancopoulos, G. D., Weinreich, D. M., Kyratsous, C. A., & Sivapalasingam, S.
Venue
Clinical Infectious Diseases
Published
2020-09-08
Volume
73
Issue
11
Pages
e4400-e4408
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3084204945
Cited by
167
References
1
FWCI
11.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. https://app.cochat.ai/papers/10.1093/cid/ciaa951
The paper
Simões, E. A. F., Forleo-Neto, E., Geba, G. P., Kamal, M., Yang, F., Cicirello, H., Houghton, M. R., Rideman, R., Zhao, Q., Benvin, S. L., Hawes, A., Fuller, E. D., Wloga, E., Pizarro, J. M. N., Munoz, F. M., Rush, S. A., McLellan, J. S., Lipsich, L., Stahl, N., . . . Sivapalasingam, S. (2021). Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa951

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.